Evaluation of tissue-engineered vascular autografts.

This study evaluated the endothelial function and mechanical properties of tissue-engineered vascular autografts (TEVAs) constructed with autologous mononuclear bone marrow cells (MN-BMCs) and a biodegradable scaffold using a canine inferior vena cava (IVC) model. MN-BMCs were obtained from a dog and seeded onto a biodegradable tubular scaffold consisting of polyglycolide fiber and poly(L-lactide-co-epsilon-caprolactone) sponge. This scaffold was implanted in the IVC of the same dog on the day of surgery. TEVAs were analyzed biochemically, biomechanically, and histologically after implantation. When TEVAs were explanted and stimulated with acetylcholine at 1 month, they produced nitrates and nitrites dose dependently. N(G)-nitro-L-arginine methylester significantly inhibited these reactions. With stimulation by acetylcholine, factor VIII-positive cells of TEVAs produced endothelial nitric oxide synthase proteins, and the ratio of endothelial nitric oxide synthase/s17 mRNA was similar among native IVC and TEVAs 1 and 3 months after implantation. TEVAs had biochemical properties and wall thickness similar to those of native IVC at 6 months after implantation, and tolerated venous pressure well without any problems such as calcification. The number of inflammatory cells in TEVAs and the ratio of CD4/s17 mRNA decreased significantly with time. These results indicate that TEVAs are a biocompatible material with functional endothelial cells and biomechanical properties and do not have unwanted side effects.

[1]  D. Stewart,et al.  Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. , 2003, The American journal of pathology.

[2]  Narutoshi Hibino,et al.  Successful application of tissue engineered vascular autografts: clinical experience. , 2003, Biomaterials.

[3]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[4]  Y. Ikada,et al.  First Evidence That Bone Marrow Cells Contribute to the Construction of Tissue-Engineered Vascular Autografts In Vivo , 2003, Circulation.

[5]  G. Koh,et al.  Molecular Cloning, Expression, and Characterization of Angiopoietin-related Protein , 1999, The Journal of Biological Chemistry.

[6]  S. Moncada,et al.  The L-arginine-nitric oxide pathway. , 1993, The New England journal of medicine.

[7]  G. Garcı́a-Cardeña,et al.  Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.

[8]  J. Chae,et al.  Coadministration of Angiopoietin-1 and Vascular Endothelial Growth Factor Enhances Collateral Vascularization , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[9]  D. Stewart,et al.  Overexpression of endothelial NO synthase induces angiogenesis in a co-culture model. , 2002, Cardiovascular research.

[10]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[11]  M. DeRuiter,et al.  Decellularization of rat aortic valve allografts reduces leaflet destruction and extracellular matrix remodeling. , 2003, The Journal of thoracic and cardiovascular surgery.

[12]  J. Dambrosia,et al.  A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. , 1993, The New England journal of medicine.

[13]  S. Rafii,et al.  Evidence for circulating bone marrow-derived endothelial cells. , 1998, Blood.

[14]  S. Liu,et al.  Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. , 1993, The American journal of physiology.

[15]  S. Moncada,et al.  An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Huang,et al.  Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. , 1998, The Journal of clinical investigation.

[17]  A. Kosaki,et al.  Implantation of Bone Marrow Mononuclear Cells Into Ischemic Myocardium Enhances Collateral Perfusion and Regional Function via Side Supply of Angioblasts, Angiogenic Ligands, and Cytokines , 2001, Circulation.

[18]  H. Hagiwara,et al.  Inhibition of ossification in vivo and differentiation of osteoblasts in vitro by tributyltin. , 2004, Biochemical pharmacology.

[19]  N. Hibino,et al.  Extracardiac total cavopulmonary connection using a tissue-engineered graft. , 2003, The Journal of thoracic and cardiovascular surgery.

[20]  李幼升,et al.  Ph , 1989 .

[21]  S Amerini,et al.  Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. , 1994, The Journal of clinical investigation.

[22]  C. Maggi,et al.  Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. , 1995, The American journal of physiology.

[23]  D. Stewart,et al.  Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. , 1998, Circulation research.

[24]  H. Granger,et al.  Nitric oxide promotes DNA synthesis and cyclic GMP formation in endothelial cells from postcapillary venules. , 1993, Biochemical and biophysical research communications.

[25]  J. Isner,et al.  Role of endothelial nitric oxide synthase in endothelial cell migration. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[26]  M. Morishima,et al.  Inhibition of outflow cushion mesenchyme formation in retinoic acid-induced complete transposition of the great arteries. , 1996, Cardiovascular research.

[27]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. , 1997, Circulation.